Jie Xiong

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Radiation Therapy

Ejection Fraction

Top Venues

Signal transduction and targeted therapy

British journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei Li Zhao
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei Li Zhao
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei Li Zhao
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Jie Xiong, Shu Cheng, Xiao Gao, Shan-He Yu, Yu-Ting Dai, Xin-Yun Huang, Hui-Juan Zhong, Chao-Fu Wang, Hong-Mei Yi, Hao Zhang, Wei-Guo Cao, Rong Li, Wei Tang, Yan Zhao, Peng-Peng Xu, Li Wang, Wei Li Zhao
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Jie Xiong, Wei Li Zhao
A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma. British journal of haematology (2023)